EP2029743A4 - METHOD FOR DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS - Google Patents

METHOD FOR DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS

Info

Publication number
EP2029743A4
EP2029743A4 EP07795515A EP07795515A EP2029743A4 EP 2029743 A4 EP2029743 A4 EP 2029743A4 EP 07795515 A EP07795515 A EP 07795515A EP 07795515 A EP07795515 A EP 07795515A EP 2029743 A4 EP2029743 A4 EP 2029743A4
Authority
EP
European Patent Office
Prior art keywords
pregnancy
diagnosing
methods
treating complications
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07795515A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2029743A1 (en
Inventor
S Ananth Karumanchi
Vikas P Sukhatme
Mourad Toporsian
Michelle V Letarte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Beth Israel Deaconess Medical Center Inc
Original Assignee
Hospital for Sick Children HSC
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/443,920 external-priority patent/US7740849B2/en
Application filed by Hospital for Sick Children HSC, Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Hospital for Sick Children HSC
Publication of EP2029743A1 publication Critical patent/EP2029743A1/en
Publication of EP2029743A4 publication Critical patent/EP2029743A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
EP07795515A 2006-05-31 2007-05-31 METHOD FOR DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS Withdrawn EP2029743A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/443,920 US7740849B2 (en) 2004-09-24 2006-05-31 Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US85276106P 2006-10-19 2006-10-19
PCT/US2007/012787 WO2008030283A1 (en) 2006-05-31 2007-05-31 Methods of diagnosing and treating complications of pregnancy

Publications (2)

Publication Number Publication Date
EP2029743A1 EP2029743A1 (en) 2009-03-04
EP2029743A4 true EP2029743A4 (en) 2010-12-08

Family

ID=39157545

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07795515A Withdrawn EP2029743A4 (en) 2006-05-31 2007-05-31 METHOD FOR DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS

Country Status (9)

Country Link
EP (1) EP2029743A4 (es)
JP (1) JP2009538915A (es)
KR (1) KR20090040874A (es)
CN (1) CN101517078A (es)
AU (1) AU2007293475A1 (es)
BR (1) BRPI0713122A2 (es)
CA (1) CA2654283A1 (es)
MX (1) MX2008015197A (es)
WO (1) WO2008030283A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060067937A1 (en) 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
DE602005023216D1 (de) 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
US20100016173A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
CN102414566B (zh) * 2009-04-23 2015-04-01 沃莱克公司 确定母体健康风险的方法
BR112012024175A2 (pt) * 2010-03-24 2016-07-05 Preelumina Diagnostics Ab hbf e a1m como marcadores de estágio precoce para preeclampsia
WO2011128357A2 (en) * 2010-04-13 2011-10-20 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
US20110251094A1 (en) 2010-04-13 2011-10-13 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
JP5959506B2 (ja) 2010-05-14 2016-08-02 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 妊娠合併症を治療するための体外デバイスおよび方法
CN102058435B (zh) * 2011-01-17 2012-05-09 北京工业大学 基于理化和血流动力学信息的妊娠期高血压风险监测装置
WO2013000992A1 (en) 2011-06-28 2013-01-03 Vitateq Biotechnology Gmbh Method for diagnosing preeclampsia
ES2714373T3 (es) * 2011-08-01 2019-05-28 Tufts Medical Ct Inc Anticuerpo específico de endoglina para uso en un método de tratamiento de la insuficiencia cardíaca y de afecciones relacionadas
US20140141456A1 (en) * 2012-08-30 2014-05-22 Ansh Labs, LLC Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
KR101417379B1 (ko) * 2012-10-30 2014-07-10 곽호석 질량분석기를 이용한 태아의 폐 성숙도 진단방법
CN103235142B (zh) * 2013-04-28 2015-04-15 成都中医药大学 一种孕妇初次妊娠筛查试剂盒
CN103207274B (zh) * 2013-04-28 2015-02-25 成都中医药大学 一种胎儿7号染色体异常疾病的筛查试剂盒
CA3018191C (en) * 2016-03-31 2022-01-25 ImMutriX Therapeutics, Inc. Method for extracorporeal treatment of preeclampsia and related disorders
CN113919453B (zh) * 2021-09-13 2024-06-11 深圳大学龙华生物产业创新研究院 用于记录生物特征的区块链集成系统
CN113933129B (zh) * 2021-09-14 2024-01-12 深圳大学 子痫前期诊断试剂盒以及荧光染料的应用
CN115791340B (zh) * 2023-01-17 2023-05-02 北京水木济衡生物技术有限公司 一种子痫复合质控品及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034507A2 (en) * 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
WO2000062605A1 (en) * 1999-04-16 2000-10-26 Yale University eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING
WO2002086497A2 (en) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034507A2 (en) * 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008030283A1 *

Also Published As

Publication number Publication date
CA2654283A1 (en) 2008-03-13
CN101517078A (zh) 2009-08-26
JP2009538915A (ja) 2009-11-12
BRPI0713122A2 (pt) 2012-04-17
WO2008030283A1 (en) 2008-03-13
MX2008015197A (es) 2009-06-23
EP2029743A1 (en) 2009-03-04
KR20090040874A (ko) 2009-04-27
AU2007293475A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
EP2029743A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS
EP2027602A4 (en) LIGHTING DEVICE AND METHOD OF MAKING
TWI372796B (en) Sapphire substrates and methods of making same
TWI350784B (en) Sapphire substrates and methods of making same
ZA200901615B (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
EP2088952A4 (en) METHODS AND DEVICES FOR PROCESSING FABRICS
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
HK1123961A1 (en) Tissue fasteners and related insertion devices
ZA200807590B (en) Diagnostics and treatments for tumors
PT2520295T (pt) Métodos para prevenir e tratar a mucosite
GB0603295D0 (en) Methods and kits
EP1909911A4 (en) METHODS AND COMPOSITIONS FOR INCREASING CHANCES OF PREGNANCY
GB0608647D0 (en) Methods of diagnosis and treatment
GB0601557D0 (en) Vehicle and method of modification thereof
EP2091551A4 (en) METHOD FOR DIAGNOSING AND TREATING ASTHMA
EP2171086A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1859725A4 (en) ENDOSCOPE AND REPAIR METHOD
HK1157672A1 (en) Lash enhancement composition and method of treatment
EP1906969A4 (en) METHOD FOR TREATING AND DIAGNOSIS OF COMPLICATIONS IN AN EARLY BIRTH
GB0613970D0 (en) Vehicle and method of modification thereof
EP2099933A4 (en) HYPOXIA-ASSOCIATED GENES AND PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF PREGNANCY-RELATED COMPLICATIONS
EP2099491A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
GB0718918D0 (en) Compositions and methods for treating skin conditions
EP2052668A4 (en) ENDOSCOPE AND ENDOSCOPINE PURGING PROCEDURE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE HOSPITAL FOR SICK CHILDREN

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE HOSPITAL FOR SICK CHILDREN

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125675

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20101109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110607

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1125675

Country of ref document: HK